Autolus Announces Proposed Public Offering in the United States
December 08 2022 - 04:03PM
GlobeNewswire Inc.
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage
biopharmaceutical company developing next-generation programmed T
cell therapies, today announced that it has commenced an
underwritten public offering of American Depositary Shares
(“ADSs”), each ADS representing one ordinary share. All ADSs to be
sold in the proposed offering will be offered by Autolus. Autolus
also intends to grant the underwriters a 30-day option to purchase
up to 15 percent of the ADSs sold in connection with the offering
at the public offering price, on the same terms and conditions. The
offering is subject to market conditions, and there can be no
assurance as to whether or when the offering may be completed or
the actual size or terms of the offering.
Jefferies LLC, William Blair & Company, L.L.C. and Wells
Fargo Securities, LLC are acting as joint bookrunners for the
offering.
The securities are being offered pursuant to an effective shelf
registration statement that was previously filed with the
Securities and Exchange Commission (“SEC”). The offering will be
made only by means of a written prospectus and prospectus
supplement that form a part of the registration statement, which,
for the avoidance of doubt, will not constitute a “prospectus” for
the purposes of the Regulation (EU) 2017/1129 and has not been
reviewed by any competent authority in any member state in the
European Economic Area. A preliminary prospectus supplement
relating to the securities will be filed with the SEC and will be
available on the SEC’s website at www.sec.gov.
When available, copies of the preliminary prospectus supplement
and the accompanying prospectus relating to these securities may be
obtained for free from the joint book-running managers for the
offering, Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by
telephone at (877) 821-7388 or by email at
Prospectus_Department@Jefferies.com; William Blair & Company,
L.L.C., Attention: Prospectus Department, 150 North Riverside
Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by
email at prospectus@williamblair.com; or Wells Fargo Securities,
LLC, Attention: Equity Syndicate Department, 500 West 33rd Street,
New York, New York, 10001, at (833) 690-2713 or email a request to
cmclientsupport@wellsfargo.com. For the avoidance of doubt, such
prospectus will not constitute a “prospectus” for the purposes of
Regulation (EU) 2017/1129 and will not have been reviewed by any
competent authority in any member state in the European Economic
Area.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy securities, and shall not
constitute an offer, solicitation or sale in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of that
jurisdiction.
About Autolus
Autolus is a clinical-stage biopharmaceutical company developing
next-generation, programmed T cell therapies for the treatment of
cancer. Using a broad suite of proprietary and modular T cell
programming technologies, the company is engineering precisely
targeted, controlled and highly active T cell therapies that are
designed to better recognize cancer cells, break down their defense
mechanisms and eliminate these cells. Autolus has a pipeline of
product candidates in development for the treatment of
hematological malignancies and solid tumors.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995, including statements with
regard to Autolus’ proposed securities offering. Words such as
“anticipates,” “believes,” “expects,” “intends,” “projects,” and
“future” or similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
subject to the inherent uncertainties in predicting future results
and conditions and no assurance can be given that the proposed
securities offering discussed above will be consummated on the
terms described or at all. Completion of the proposed offering and
the terms thereof are subject to numerous factors, many of which
are beyond the control of Autolus, including, without limitation,
market conditions, failure of customary closing conditions and the
risk factors and other matters set forth in Autolus’ Annual Report
on Form 20-F for the year ended December 31, 2021 and other filings
Autolus makes with the SEC from time to time. Autolus undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as may be required by law.
Contacts:
Olivia Manser+44 (0) 7780 471568 o.manser@autolus.com
Julia Wilson +44 (0) 7818 430877 j.wilson@autolus.com
Susan A Noonan S.A. Noonan
Communications+1-917-513-5303susan@sanoonan.com
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From May 2023 to May 2023
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From May 2022 to May 2023